LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA: WHETHER ADVANTAGES ARE OBVIOUS?


如何引用文章

全文:

详细

The article presents the data on epidemiological studies of community-acquired pneumonia (CAP). The problems of growth of antibiotic resistance of major pathogens of respiratory tract infections in 1995-2009 are discussed. Comparison of the effectiveness of monotherapy with respiratory fluoroquinolones or combination of β-lactam antibiotic and macrolide in the initial treatment of CAP is of great interest.

参考

  1. Чучалин А.Г., Синопальников А.И., Козлов Р.С. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике / Пособие для врачей. М., 2010. 106 с.
  2. Mandell LA, Wunderlink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(2):S27-72.
  3. Падейская Е.Н. Левофлоксацин (Таваник) - препарат группы фторхинолонов для лечения инфекционных заболеваний с широкими показаниями к применению // Качественная клиническая практика 2002. № 2. С. 80-95.
  4. Сидоренко С.В. Фторированные хинолоны - спектр активности и клиническое значение // Клин. антибиотикотер. 2001. № (5-6). С. 31-5.
  5. Paladino JA. Is more than one quinolone needed in clinical practice. Ann Pharmacother 2001;35:1085-95.
  6. Tavanic (levofloxacin) iv/oral. Scientific Product Monograph. Hoechst-Marion Russel, 1999.
  7. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
  8. Fu KP, Foleno B, Rosenthale ME. The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin. Diagn Microbiol Infect Dis 1992;15:375-78.
  9. Licata L, Smith CE, Goldshmidt RM, et al. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:950-55.
  10. Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin and clarithromycin against 20 pneumococci. Antimicrob Agents Chemother 1998;42(5):1253-55.
  11. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63(24):2769-802.
  12. Сидоренко С.В. Тенденции в распространении антибиотикорезистентности среди возбудителей внебольничной инфекции на территории Российской Федерации //Consilium medicum 2007. № 1. Т. 09.
  13. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54(1):i7-15.
  14. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004;48(1):56-65.
  15. Goff DA, Dowzicky MJ. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol 2007;56(9):1189-195.
  16. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52(2):229-46.
  17. Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis 2007;58 (1):9-17.
  18. Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003;47(6):1790-97.
  19. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002;36:1938-43.
  20. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized clinical trials. CMAJ 2008;179(12):1269-77.
  21. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II // Клин. биол. и антимикроб. химиотер. 2006. № 1 (8). С. 33-47.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##